Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial

查看全文 作　　者：Mu oz N; Manalastas R Jr; Pitisuttithum P; 出　　处：《Lancet》索引2009年第373卷第9679期,共0页